Research programme: diabetic nephropathy therapies - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
Latest Information Update: 25 Aug 2014
At a glance
- Originator AstraZeneca; Mitsubishi Tanabe Pharma Corporation
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetic nephropathies
Most Recent Events
- 20 Aug 2014 Early research in Diabetic nephropathies in Sweden and Japan (unspecified route)